Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6490
    +0.0001 (+0.02%)
     

  • OIL

    82.75
    -0.61 (-0.73%)
     

  • GOLD

    2,336.80
    -5.30 (-0.23%)
     

  • Bitcoin AUD

    99,662.20
    -2,984.11 (-2.91%)
     

  • CMC Crypto 200

    1,398.08
    -26.02 (-1.83%)
     

  • AUD/EUR

    0.6071
    +0.0015 (+0.24%)
     

  • AUD/NZD

    1.0951
    +0.0021 (+0.19%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,451.18
    -20.29 (-0.12%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,355.59
    -148.10 (-0.38%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Better Long-Term Buy: AbbVie or Novo Nordisk?

Jim Halley, The Motley Fool
·5-min read
Better Long-Term Buy: AbbVie or Novo Nordisk?

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions. Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year. AbbVie, on the other hand, thanks to the loss of patent protection for immunology blockbuster Humira, has forecasted 2023 adjusted earnings per share (EPS) to drop by 20% to 23%, from 2022 levels.

Continue reading